Breast cancer - gemcitabine: review decision - May 2010
Review of NICE Technology Appraisal Guidance No 116; Gemcitabine for the treatment of metastatic breast cancer
The Institute was proposing that the guidance should be transferred to the static guidance list.
During consultation, the majority of comments received by the Institute agreed with the proposal put forward. After consideration of all of the comments (attached as Appendix A), the Institute’s Guidance Executive has decided to proceed with the proposal and the guidance will be transferred on to the static list.
Topics on the static list may be transferred back to the active list for further appraisal if new evidence becomes available that is likely to have a material effect on the last guidance issued.
This page was last updated: 28 December 2010